The Efficacy of Tucatinib-based Therapeutic Approaches for HER2-positive Breast Cancer

Overview

Journal Mil Med Res

Publisher Biomed Central

Specialty Emergency Medicine

Date 2022 Jul 12

PMID 35820970

Authors

Zaid Sirhan

Anita Thyagarajan

Ravi P Sahu

Affiliations

Soon will be listed here.

Abstract

Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in approximately 15-20% of breast cancer cases. HER2 is a member of the epidermal growth factor receptor (EGFR) family with tyrosinase kinase activity, and its overexpression is linked to poor prognosis and shorter progression-free survival (PFS) and overall survival (OS). Among various treatment options, HER2-targeting monoclonal antibodies and tyrosine kinase inhibitors (TKIs) have mostly been applied in recent decades to treat HER2-positive (HER2+) breast cancer patients. Although positive clinical outcomes were documented in both advanced disease and neoadjuvant settings, the development of resistance mechanisms to such approaches has been one of the major challenges with the continuous usage of these drugs. In addition, patients who experience disease progression after treatment with multiple HER2-targeted therapies often have limited treatment options. The Food and Drug Administration (FDA) has recently approved a new TKI (i.e., tucatinib) for use in combination with immunotherapy and/or chemotherapeutic agents for the treatment of advanced-stage/metastatic HER2+ breast cancer. This review highlights recent updates on the efficacy of tucatinib-based therapeutic approaches in experimental models as well as in the clinical settings of HER2+ breast cancer.

Citing Articles

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs.

Zhang X, Yin Y, Yu Q, Chen X, Cheng Y Front Oncol. 2025; 14:1492203.

PMID: 39991185 PMC: 11842234. DOI: 10.3389/fonc.2024.1492203.

Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.

Imam M, Ji J, Zhang Z, Yan S Front Pharmacol. 2025; 15:1493188.

PMID: 39867656 PMC: 11757020. DOI: 10.3389/fphar.2024.1493188.

Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.

Ma S, Zhou Y, Ma D, Qi X, Jiang J Am J Cancer Res. 2024; 14(9):4218-4235.

PMID: 39417184 PMC: 11477836. DOI: 10.62347/JWHA6355.

Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer.

Yang L, Chen S, Wang M, Peng S, Zhao H, Yang P Heliyon. 2024; 10(19):e38221.

PMID: 39386771 PMC: 11462380. DOI: 10.1016/j.heliyon.2024.e38221.

Elucidating the evolving role of cuproptosis in breast cancer progression.

Zhu Z, Zhu K, Zhang J, Zhou Y, Zhang Q Int J Biol Sci. 2024; 20(12):4872-4887.

PMID: 39309446 PMC: 11414396. DOI: 10.7150/ijbs.98806.

References

Murthy R, Borges V, Conlin A, Chaves J, Chamberlain M, Gray T . Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018; 19(7):880-888. DOI: 10.1016/S1470-2045(18)30256-0. View

Freudenberg J, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene M . The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol. 2009; 87(1):1-11. PMC: 2735009. DOI: 10.1016/j.yexmp.2009.05.001. View

Pietila M, Sahgal P, Peuhu E, Jantti N, Paatero I, Narva E . SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019; 10(1):2340. PMC: 6538630. DOI: 10.1038/s41467-019-10275-0. View

Molina M, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J . Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001; 61(12):4744-9. View

Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G . Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007; 67(24):11991-9. DOI: 10.1158/0008-5472.CAN-07-2068. View

OSullivan C, Davarpanah N, Abraham J, Bates S . Current challenges in the management of breast cancer brain metastases. Semin Oncol. 2017; 44(2):85-100. DOI: 10.1053/j.seminoncol.2017.06.006. View

Makarem N, Chandran U, Bandera E, Parekh N . Dietary fat in breast cancer survival. Annu Rev Nutr. 2013; 33:319-48. PMC: 3853119. DOI: 10.1146/annurev-nutr-112912-095300. View

Cuello M, Ettenberg S, Clark A, Keane M, Posner R, Nau M . Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001; 61(12):4892-900. View

Borges V, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I . Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018; 4(9):1214-1220. PMC: 6143009. DOI: 10.1001/jamaoncol.2018.1812. View

10.

Cronin K, Harlan L, Dodd K, Abrams J, Ballard-Barbash R . Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9):963-8. PMC: 5094051. DOI: 10.3109/07357907.2010.496759. View

11.

Hsu J, Hung M . The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016; 35(4):575-588. PMC: 5215954. DOI: 10.1007/s10555-016-9649-6. View

12.

Metzger Filho O, Leone J, Li T, Tan-Wasielewski Z, Trippa L, Barry W . Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020; 31(9):1231-1239. DOI: 10.1016/j.annonc.2020.05.014. View

13.

Di Fiore P, PIERCE J, Kraus M, Segatto O, King C, Aaronson S . erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237(4811):178-82. DOI: 10.1126/science.2885917. View

14.

Hubbard S, Till J . Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000; 69:373-98. DOI: 10.1146/annurev.biochem.69.1.373. View

15.

Barnard M, Boeke C, Tamimi R . Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta. 2015; 1856(1):73-85. DOI: 10.1016/j.bbcan.2015.06.002. View

16.

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

17.

Xuhong J, Qi X, Zhang Y, Jiang J . Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019; 9(10):2103-2119. PMC: 6834479. View

18.

Kunte S, Abraham J, Montero A . Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020; 126(19):4278-4288. DOI: 10.1002/cncr.33102. View

19.

Swain S, Miles D, Kim S, Im Y, Im S, Semiglazov V . Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020; 21(4):519-530. DOI: 10.1016/S1470-2045(19)30863-0. View

20.

Brandao M, Ponde N, Poggio F, Kotecki N, Salis M, Lambertini M . Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects. Expert Rev Anticancer Ther. 2018; 18(7):629-649. DOI: 10.1080/14737140.2018.1477596. View